Alberta to assess a new screening strategy using MTI's PolypDx™

Metabolomic Technologies Inc. today announced the launch of a $1.4 million project that will evaluate a new colorectal cancer screening strategy using PolypDx™, the first and only urine test for the detection and prevention of colorectal cancer. The project, called the Canadian Assessment of PolypDx™ (CAP), will engage expert physicians, clinicians, patients and laboratory specialists to assess the benefits of the test to colorectal cancer screening rates in 3000 patients in five regions located throughout Alberta.